Medical company Summit Medical Group said on Monday that the Department of Ear Nose & Throat/Allergy conducted a clinical trial that led the US Food & Drug Administration (FDA) to approve the nasal spay XHANCE (fluticasone proprionate) for the treatment of nasal polyps in patients 18 years of age or older.
The XHANCE clinical trial is reportedly part of the company's larger initiative to advance medicine.
Currently, the company is involved in 31 active clinical trials, which are critical to the development of new therapies, including finding innovative treatments for cancer, rheumatoid arthritis, type 2 diabetes as well as allergies.
In the US, about 10 million people suffer from the benign growths that block the nasal passages and cause congestion, pain and pressure, sinus infections and difficulty breathing.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults